Search results
Showing 886 to 900 of 1808 results for nice guidelines
Find out more about NICE technology appraisals advisory committee D members
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy.
The OPTIMIZER smart system for managing heart failure (MIB186)
NICE has developed a medtech innovation briefing (MIB) on the OPTIMIZER smart system for managing heart failure .
MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)
NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .
In development [GID-NG10431] Expected publication date: 26 March 2025
NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .
NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds
NICE has developed a medtech innovation briefing (MIB) on the Quantitative Timed Up and Go (QTUG)
NICE has developed a medtech innovation briefing (MIB) on Stockholm3 for prostate cancer screening .
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)
Evidence-based recommendations on carmustine implants (Gliadel) and temozolomide for treating newly diagnosed high-grade glioma in adults.
NICE has developed a medtech innovation briefing (MIB) on Thora 3Di for assessing asthma in children .
NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .
Healthy start vitamins: special report on cost effectiveness (ECD5)
Healthy start vitamins: special report on cost effectiveness